Feature | April 09, 2015

Physicians Pioneer Use of Stereotactic Body Radiation for Deadly Kidney Cancer Complication

New technique provides alternative to surgery for tumor removal

UT Southwestern, kidney cancer, stereotactic body radiation, SABR, IVC-TT

Raquibul Hannan, M.D., left, and Robert Timmerman, M.D., led a team that successfully used stereotactic body radiation therapy for the first time to treat an often deadly complication of kidney cancer. Image courtesy of UT Southwestern Medical Center.

April 9, 2015 — UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often-deadly complication of kidney cancer.

Two case studies provide an important potential new avenue for treatment of these types of tumors, which are resistant to traditional radiation therapies and difficult to manage even with surgery, the current standard of care.

“Our case studies showed similar survival with the use of stereotactic radiation therapy compared with surgery,” said lead author Raquibul Hannan, M.D., assistant professor of radiation oncology and co-leader of the Kidney Cancer Program at the Harold C. Simmons Comprehensive Cancer Center. “This result is important because people with this disease have a traditionally poor prognosis and few options.”

The stereotactic ablative radiation therapy (SABR) was used to treat inferior vena cava tumor thrombus (IVC-TT) that reached the heart, a complication of kidney cancer in which the tumor extends into the venous system ? the system of veins that return blood to the heart. An estimated 4 to 36 percent of kidney tumors are associated with IVC-TT, according to the study in Cancer Biology & Therapy.

"Removing the tumor surgically currently is the only treatment proven effective. It is still considered an extremely difficult and delicate surgery, with high rates of complications and cancer recurrence,” said Vitaly Margulis, M.D., associate professor of urology. As detailed in a recent study by Margulis in The Journal of Urology, “Patients with the disease who undergo surgery have a mortality rate that can be as high as 10 percent, depending on the location of the tumor and its growth into the venous system. There are currently no alternatives for those who are not surgical candidates.”

“For these reasons, finding new therapies such as stereotactic radiation therapy are desperately needed,” Hannan said. “This innovative proof-of-principle was a critical first step for determining whether our approach will ultimately prove to be effective.”

Kidney cancer is a common and often deadly malignancy, with more than 63,900 new cases and 13,800 deaths predicted in the United Staets in 2014. And it is on the rise— research suggests kidney cancer cases are increasing at a rate of about 4 percent annually. In addition, IVC-TT can be difficult to diagnose because patients may have no symptoms or a wide variety of symptoms that can be attributable to many other conditions. Left untreated, IVC-TT can lead to severe complications including pulmonary tumor embolus (tumor clots in the lung), Budd-Chiari syndrome (a serious liver condition) and even fatality.

These case studies – one case of recurrent and another with unresectable IVC-TT ? demonstrate that SABR can be an effective treatment. The reported survival times of 18 months and 24 months were comparable to standard surgical outcomes and both improved symptomatically, and did not experience any acute or late treatment-related toxicity, the researchers reported. UT Southwestern’s kidney cancer team hopes to follow up with a study to evaluate the application of SABR for IVC-TT in conjunction with surgery.

For more information: www.utsouthwestern.edu

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init